1. Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. PloS one. 2013;8(6):e66312.

2. Casado I, Domínguez A, Toledo D, Chamorro J, Force L, Soldevila N, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert review of vaccines. 2016;15(3):425-32.

3. Mosnier A, Daviaud I, Caini S, Berche H, Mansuy JM, van der Werf S, et al. Does seasonal vaccination affect the clinical presentation of influenza among the elderly? A cross-sectional analysis in the outpatient setting in France, 2003-2014. Vaccine. 2017;35(16):2076-83.

4. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013;31(50):6030-3.

5. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017;35(4):513-20.

6. Lee WJ, Chen LK, Tang GJ, Lan TY. The impact of influenza vaccination on hospitalizations and mortality among frail older people. Journal of the American Medical Directors Association. 2014;15(4):256-60.

7. Cruzeta AP, Schneider IJ, Traebert J. Impact of seasonality and annual immunization of elderly people upon influenza-related hospitalization rates. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2013;17(12):e1194-7.

8. Torner N, Navas E, Soldevila N, Toledo D, Navarro G, Morillo A, et al. Costs associated with influenza-related hospitalization in the elderly. Human vaccines & immunotherapeutics. 2017;13(2):412-6.

9. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711-20.

10. Hughes MM, Reed C, Flannery B, Garg S, Singleton JA, Fry AM, Rolfes MA. Projected Population Benefit of Increased Effectiveness and Coverage of Influenza Vaccination on Influenza Burden in the United States. Clin Infect Dis. 2020;70(12):2496-502.

11. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine. 2008;26(26):3209-22.

12. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959-65.

13. Tsai TF. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infection & chemotherapy. 2013;45(2):159-74.

14. Cowling BJ, Thompson MG, Ng TWY, Fang VJ, Perera R, Leung NHL, et al. Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults. The Journal of infectious diseases. 2020;222(8):1383-91.

15. Pott H, Andrew MK, Shaffelburg Z, Nichols MK, Ye L, ElSherif M, et al. Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). Vaccine. 2023;41(42):6359-65.

16. Nowlan ML. Review of evidence to inform the New Zealand National Immunisation Programme, 2025: Influenza – enhanced vaccines. . Auckland, New Zealand: Immunisation Advisory Centre, University of Auckland; 2025 October 2025.

17. Imran M, Puig-Barbera J, Ortiz JR, Fischer L, O'Brien D, Bonafede M, et al. Relative effectiveness of MF59 adjuvanted trivalent influenza vaccine vs nonadjuvanted vaccines during the 2019-2020 influenza season. Open Forum Infect Dis. 2022;9(5):ofac167.

18. Lapi F, Marconi E, Simonetti M, Baldo V, Rossi A, Sessa A, Cricelli C. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines. 2019;18(6):663-70.

19. Puig-Barberà J, Díez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, Hoyos SP, Vidal DG. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25(42):7313-21.

20. Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813-23.

21. Gärtner BC, Weinke T, Wahle K, Kwetkat A, Beier D, Schmidt KJ, Schwarz TF. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data. Vaccine. 2022;40(22):2999-3008.

‍

‍